Results 41 to 50 of about 60,559 (162)

Plasma Tissue Factor Pathway Inhibitor Levels in Angiographically Defined Coronary Artery Disease Among Saudis

Oman Medical Journal, 2013
Objectives: This study was aimed to determine plasma levels of total (TFPI-T) and free (TFPI-F) tissue factor pathway inhibitor, plasminogen activator inhibitor-1 (PAI-1), and tissue plasminogen activator (t-PA) in a cohort of Saudi patients with chronic
Syed Shahid Habib
doaj   +1 more source

Components of the plasminogen activation system promote engraftment of porous polyethylene biomaterial via common and distinct effects. [PDF]

PLoS ONE, 2015
Rapid fibrovascularization is a prerequisite for successful biomaterial engraftment. In addition to their well-known roles in fibrinolysis, urokinase-type plasminogen activator (uPA) and tissue plasminogen activator (tPA) or their inhibitor plasminogen ...
Christoph A Reichel, Maximilian E T Hessenauer, Kerstin Pflieger, Markus Rehberg, Sandip M Kanse, Stefan Zahler, Fritz Krombach, Alexander Berghaus, Sebastian Strieth   +8 more
doaj   +1 more source

Decrease of fibrinolytic potential in the occurrence of cerebral ischemia [PDF]

Journal of Medical Biochemistry, 2008
One of the most present clinical manifestations of long and progressive atherothrombotic occurrences is the ischemic cerebrovascular insult, one of the leading causes of death and illness in the world.
Vučković Biljana, Đerić Mirjana, Ilić Tatjana, Čanak Višnja, Žarkov Marija   +4 more
doaj  

Impaired Fibrinolysis in Pregnancy Failure

Journal of Aziz Fatimah Medical and Dental College
Objective: To explore the association between plasma plasminogen activator inhibitor 1 (PAI-1) levels and women experiencing recurrent miscarriages with no live births to those who have had one or more live births.
Samina Mohyuddin, Rabab Zehra , Samar Ekram , Zareen Naz, Shahida Kashif, Badar Jahan   +5 more
doaj   +3 more sources

Prognostic significance of uPA/PAI-1 level, HER2 status, and traditional histologic factors for survival in node-negative breast cancer patients

Radiology and Oncology, 2016
The association of HER2 status with urokinase plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1) levels raises the question whether uPA/PAI-1 level carries additional clinically relevant prognostic information independently from ...
Dovnik Nina Fokter, Takac Iztok
doaj   +1 more source

Assessment of plasminogen activator inhibitor-1 in obese Egyptian children

Egyptian Pediatric Association Gazette, 2020
Background Plasminogen activator inhibitor-1 (PAI-1) is mainly produced in the liver and in the adipose tissue. Normal fibrin clearance mechanisms were found to be affected by high plasma PAI-1 levels and thus increases risk of thrombosis. The aim of the
Marwa Farouk Mira, Ghada Mohammad Anwar, Azza Mohamed Sarry EL-Din, Safinaz Mohammed Megahed   +3 more
doaj   +1 more source

Plasminogen activator inhibitor-1: a review Plasminogen-Aktivator-Inhibitor-1: eine Übersicht [PDF]

LaboratoriumsMedizin, 2005
Abstract Plasminogen activator inhibitor-1 (PAI-1) is the most potent inhibitor of both tissue type (t-PA) and urokinase type plasminogen activator (u-PA) and thus regulates fibrinolysis as well as proteolysis, cell migration, and tumor cell invasiveness.
Markus Pihusch, Verena Pihusch, Ernst Holler   +2 more
openaire   +1 more source

Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors

Radiology and Oncology, 2015
Background. Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) play a key role in tumour invasion and metastasis. High levels of both proteolytic enzymes are associated with poor prognosis in breast cancer patients ...
Lampelj Maja, Arko Darja, Cas-Sikosek Nina, Kavalar Rajko, Ravnik Maja, Jezersek-Novakovic Barbara, Dobnik Sarah, Dovnik Nina Fokter, Takac Iztok   +8 more
doaj   +1 more source

Data in support of a central role of plasminogen activator inhibitor-2 polymorphism in recurrent cardiovascular disease risk in the setting of high HDL cholesterol and C-reactive protein using Bayesian network modeling

Data in Brief, 2016
Data is presented that was utilized as the basis for Bayesian network modeling of influence pathways focusing on the central role of a polymorphism of plasminogen activator inhibitor-2 (PAI-2) on recurrent cardiovascular disease risk in patients with ...
James P. Corsetti, Peter Salzman, Dan Ryan, Arthur J. Moss, Wojciech Zareba, Charles E. Sparks   +5 more
doaj   +1 more source

Plasminogen Activator Inhibitor-1 Levels and Polymorphisms

Archives of Pathology & Laboratory Medicine, 2002
Abstract Objective.—To review the published evidence of a relationship between levels of plasminogen activator inhibitor-1 (PAI-1) or the 4G/5G polymorphism of the PAI-1 gene and the occurrence of venous thromboembolic disease. Methods.—Review of the medical literature using computerized databases and a review of ...
openaire   +2 more sources